hrs4r
Quiero donar

PILAR BARRETINA GINESTA

Firma
PILAR BARRETINA-GINESTA
Posición
Investigador/a Pre-doctoral – R1
Investigadores/as Pre-doctorales – R1

Publicacions

0

SEOM-GEICO clinical guidelines on endometrial cancer (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24, 625-634 dx.doi.org/10.1007/s12094-022-02799-7
0

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14184414

Garcia-Casado, Z, Oaknin, A, Mendiola, M, Alkorta-Aranburu, G, Antunez-Lopez, JR, Moreno-Bueno, G, Palacios, J, Yubero, A, Marquez, R, Gallego, A, Sanchez-Heras, AB, Lopez-Guerrero, JA, Perez-Segura, C, Barretina-Ginesta, P, Alarcon, J, Gaba, L, Marquez, A, Matito, J, Cueva, J, Palacio, I, Iglesias, M, Arcusa, A, Sanchez-Lorenzo, L, Guerra-Alia, E, Romero, I, Vivancos, A

Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

Journal of Personalized Medicine, 2022, 12 dx.doi.org/10.3390/jpm12111842

Barretina-Ginesta, MP, Monk, BJ, Han, S, Pothuri, B, Auranen, A, Chase, DM, Lorusso, D, Anderson, C, Abadie-Lacourtoisie, S, Cloven, N, Braicu, EI, Amit, A, Redondo, A, Shah, R, Kebede, N, Hawkes, C, Gupta, D, Woodward, T, O'Malley, DM, Gonzalez-Martin, A

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14 dx.doi.org/10.1177/17588359221126149

Moya-Alarcón C, González-Domínguez A, Ivanova-Markova Y, Gimeno-Ballester V, BARRETINA GINESTA, PILAR, Pérez-Fidalgo JA, Redondo A

Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain

GYNECOLOGIC ONCOLOGY, 2022, 164, 406-414 dx.doi.org/10.1016/j.ygyno.2021.11.011
0

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

Journal for ImmunoTherapy of Cancer, 2021, 9 dx.doi.org/10.1136/jitc-2021-003645
0

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

FUTURE ONCOLOGY, 2021, 17, 3781-3785 dx.doi.org/10.2217/fon-2021-0598
0

Management of advanced ovarian cancer in Spain: an expert Delphi consensus

JOURNAL OF OVARIAN RESEARCH, 2021, 14, 72-72 dx.doi.org/10.1186/s13048-021-00816-x
0

SEOM clinical guideline in ovarian cancer (2020)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23, 961-968 dx.doi.org/10.1007/s12094-020-02545-x
0

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate

Cancer Management and Research, 2020, 12, 10251-10260 dx.doi.org/10.2147/CMAR.S270392

Formulari de contacte

Conoce el IDIBGI!

menu